4.5 Article

Risk of Cardiovascular Disorders in Psoriasis Patients Current and Future

Journal

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume 14, Issue 1, Pages 1-7

Publisher

ADIS INT LTD
DOI: 10.1007/s40257-012-0005-5

Keywords

-

Categories

Funding

  1. Galderma Laboratories
  2. Galderma
  3. Astellas
  4. Abbott Labs
  5. Warner Chilcott
  6. Janssen
  7. Amgen
  8. Photomedex
  9. Genentech
  10. BiogenIdec
  11. Coria/Valeant
  12. Pharmaderm
  13. Ortho Pharmaceuticals
  14. Aventis Pharmaceuticals
  15. Roche Dermatology
  16. 3M
  17. Bristol Myers Squibb
  18. Stiefel/GlaxoSmithKline
  19. Novartis
  20. Medicis
  21. Leo
  22. HanAll Pharmaceuticals
  23. Celgene
  24. Basilea
  25. Anacor

Ask authors/readers for more resources

Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available